Autologous BCMA-targeted CAR T Cells LCAR-B4822M

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of autologous peripheral blood T-lymphocytes (PBTLs) that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon administration, autologous BCMA-targeted CAR T-cells LCAR-B4822M specifically recognize and kill BCMA-expressing tumor cells. BCMA, a tumor specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily and plays a key role in plasma cell survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.

**Synonyms:** - Autologous LCAR-B4822M CAR T Cells - BCMA-specific CAR-expressing T-lymphocytes LCAR-B4822M - LCAR B4822M - LCAR-B4822M - LCAR-B4822M CAR-T-lymphocytes - LCAR-B4822M-02 Cells - LCARB4822M